Enrofloxacin 100 Injection Value Pick, 100 mL

Cattle - Single-Dose Therapy

• For the treatment of bovine respiratory disease (BRD) associated with 

  Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in beef and non-lactating dairy cattle.

• For the control of BRD in beef and non-lactating dairy cattle at high risk of developing BRD associated with M. haemolytica, P. multocida, H. somni and M. bovis.

Cattle - Multiple-Day Therapy

• For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni in beef and non-lactating dairy cattle.

Swine

• For the treatment and control of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, Streptococcus suis, Bordetella bronchiseptica andMycoplasma hyopneumoniae.

• For the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with Escherichia coli has been diagnosed.

Additional Safety Information

• Cattle: Animals intended for human consumption must not be slaughtered within 28 days from the last treatment. This product is not approved for female dairy cattle 20 months of age or older. Do not use in calves to be processed for veal.

• Swine: Animals intended for human consumption must not be slaughtered within 5 days of receiving a single-injection dose.

• Individuals with a history of hypersensitivity to quinolones should avoid this product.

• The effects of enrofloxacin on cattle or swine reproductive performance, pregnancy, and lactation have not been adequately determined.

• The long-term effects on articular joint cartilage have not been determined in pigs above market weight.

• Subcutaneous injection in cattle and swine, or intramuscular injection in swine, can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

• Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures. Quinolone-class drugs have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species.